Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

4D Molecular Therapeutics Inc (FDMT)

4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
4D Molecular Therapeutics: The Runway Math Doesn't Add Up Despite the Investor Day Optimism Barchart - Fri Aug 14, 4:01PM CDT

Barchart Research What to Expect from FDMT Earnings FDMT Generated August 14, 2026 Current Price $12.19 EPS Estimate $$-1.04 Consensus Rating Moderate Buy Average Move 5.31% 4D Molecular Therapeutics:...

FDMT : 15.83 (-1.68%)
4DMT Announces New Employment Inducement Grants GlobeNewswire - Fri Aug 14, 3:05PM CDT

EMERYVILLE, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 15.83 (-1.68%)
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones GlobeNewswire - Thu Aug 13, 3:05PM CDT

Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027  4D-150 4FRONT-1 Phase 3 topline data expected in Q2 2027 Presented positive 2-year data from 4D-150 PRISM...

FDMT : 15.83 (-1.68%)
4D Molecular Therapeutics' Gene Therapy Pipeline Faces Its First Real Commercial Scrutiny Barchart - Fri Aug 7, 4:05PM CDT

Barchart Research What to Expect from FDMT Earnings FDMT Generated August 7, 2026 Current Price $10.76 EPS Estimate $$-1.04 Consensus Rating Moderate Buy Average Move 5.31% 4D Molecular Therapeutics' Gene...

FDMT : 15.83 (-1.68%)
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population GlobeNewswire - Sat Jul 18, 2:15PM CDT

After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years  4D-150 continues to be well tolerated...

FDMT : 15.83 (-1.68%)
4DMT Announces New Employment Inducement Grants GlobeNewswire - Fri Jul 17, 3:05PM CDT

EMERYVILLE, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 15.83 (-1.68%)
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists GlobeNewswire - Tue Jun 30, 3:05PM CDT

EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 15.83 (-1.68%)
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD GlobeNewswire - Mon Jun 29, 7:00AM CDT

4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections 4FRONT-2 over-enrolled (anticipated N>500), with final patient randomization expected in Q3 2026, reflecting...

FDMT : 15.83 (-1.68%)
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital GlobeNewswire - Mon Jun 29, 7:00AM CDT

EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 15.83 (-1.68%)
HTGC : 17.13 (+0.59%)
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker GlobeNewswire - Fri Jun 26, 6:30AM CDT

ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting...

FDMT : 15.83 (-1.68%)
VANI : 1.3800 (-2.13%)

Barchart Exclusives

Microsoft vs. Broadcom: One Has 85% Upside, But I'm Picking the Other Barchart - Fri Aug 21, 6:00PM CDT
Wall Street sees 85% upside in Broadcom versus 45% for Microsoft. But bigger upside doesn't always mean the better buy. Here's why I'm sticking with Microsoft as the smarter AI stock for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.